20.500.12556/DiRROS-8619 Nove možnosti citopatološke diagnostike raka sečnega mehurja s testom UroVysion New Promises of Cytopathologic Diagnostics of Bladder cancer by Using UroVysion™ Cytopathologic examination of the urine and bladder washing is a standard method for the detection of primary bladder cancer in symptomatic patients or in patients with hematuria. The method is also very useful to follow the patients after treatment in order to detect recurrence of bladder cancer which occurs in a significant percentage of patients. Cytopathologic examination is highly accurate for the diagnosis of high grade urothelial carcinoma and carcinoma in situ. However, the method is recognized as being unreliable for the detection of low grade urothelial neoplasms. Obvious cellular and nuclear morphological signs of malignancy can be reliably recognized in high grade papillary, invasive and in situ urothelial carcinoma. Thus, less pronounced cellular atypia pose everyday diagnostic problems and atypia of low grade papillary neoplasms cannot be always reliably differentiated from atypia of some benign and post-treatment reactive changes. In the last decade a number of new urinary markers have been developed to overcome low sensitivity of urinary cytology. Although most of these tests are highly sensitive, they have lower specificity than cytology. The UroVysion test seems the most promising among the new tests. By the method of multitarget fluorescent in situ hybridisation (FISH), the test can detect several cytogenetic changes characteristic for different grades of bladder cancer. Therefore, the UroVysion test is useful for assessing neoplastic nature of cytologically undetermined atypical cells. The most recent reports claim that the UroVysion test can even detect bladder cancer before morphological changes are diagnosed in urine cytology. sečni mehur rak (medicina) citološka diagnostika true false true Slovenski jezik Angleški jezik by Authors Neznano 2018-08-31 13:26:52 2018-08-31 13:26:52 2022-08-16 10:08:14 0000-00-00 00:00:00 2009 0 0 BSDOCID151741; str. 130-132, 153 št. 2 Letn. 13 2009 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616.62-006-07 1408-1741 URN:NBN:SI:doc-9XB4AZO1 27082969 65324032 RAZ_Strojan_Flezar_Margareta_i2009.pdf RAZ_Strojan_Flezar_Margareta_i2009.pdf 1 405065A75CAC0B105E564BC9D4BDC78E 2469c6b8873f25422765bf2078fffcb31886ef92255b24c6304d216e2959ccec 52f57aa0-17b5-11ed-b6b8-001a4af901a5 20.500.12556/dirros/332157d7-d06e-461c-92c1-6a74f542b07e https://dirros.openscience.si/Dokument.php?lang=slv&id=10400 Onkološki inštitut Ljubljana Onkologija : strokovni časopis za zdravnike 0 0 0